- Home
- TMQ vs AGMB Comparison
TMQ vs AGMB Comparison
Compare TMQ & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMQ | AGMB |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Canada | Belgium |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.7M | 677.9M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | TMQ | AGMB |
|---|---|---|
| Price | $4.34 | $11.65 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 2.3M | 137.3K |
| Earning Date | 04-02-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $9.00 |
| 52 Week High | $11.29 | $17.45 |
Technical Indicators
Market Signals| Indicator | TMQ | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 53.87 | 54.88 |
| Support Level | $4.26 | $10.30 |
| Resistance Level | $4.46 | $12.21 |
| Average True Range (ATR) | 0.24 | 0.84 |
| MACD | 0.00 | 0.21 |
| Stochastic Oscillator | 46.71 | 68.15 |
Price Performance
Historical ComparisonAbout TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.